What is MariTide, and how does the monthly GIPR-antagonist/GLP-1 drug work?

The short answer

MariTide (maridebart cafraglutide) is Amgen's investigational obesity drug — a once-monthly injectable that pairs a GLP-1 receptor agonist with a GIP receptor antagonist in a single peptide-antibody molecule. In a Phase 2 trial it produced up to about 20% weight loss in people with obesity. Its standout features are monthly dosing and an unusual mechanism; it is not yet approved and is in Phase 3.

Evidence tier: Tier 1 for the published Phase 1 and Phase 2 trial results; Tier 2 for cross-trial comparisons. Educational content, not medical advice.

The key points:

• Monthly dosing — a long-acting peptide-antibody conjugate, not weekly
• Unusual mechanism: GLP-1 agonist + GIP receptor antagonist
• Phase 2: up to ~20% weight loss (obesity), ~17% with type 2 diabetes
• Tolerability is the question — high GI/discontinuation rates are being addressed in Phase 3

For the drug-class background, see the GLP-1 complete guide.

What is MariTide?

Evidence tier: 2 — established pharmacology.

MariTide, generic name maridebart cafraglutide (formerly AMG 133), is an investigational obesity treatment from Amgen. Structurally it's unusual: it's a peptide-antibody conjugate — a monoclonal antibody that antagonizes the GIP receptor, joined to two GLP-1 analogue peptides (Nature Metabolism, AMG 133 Phase 1). That antibody backbone is what gives the drug a long half-life, enabling once-monthly (or potentially less frequent) subcutaneous dosing — a meaningful contrast with the weekly injections of semaglutide and tirzepatide.

For some people, dosing frequency is a real adherence factor: twelve injections a year is a very different commitment from fifty-two. So even setting efficacy aside, a monthly obesity drug occupies a distinct and potentially attractive niche. But the more scientifically interesting feature is the mechanism — specifically that MariTide blocks the GIP receptor rather than activating it, which is the opposite of what tirzepatide does, and yet both produce substantial weight loss. That apparent paradox is worth unpacking, because it's central to understanding the drug.

Why does MariTide block GIP when tirzepatide activates it?

Evidence tier: 2 — mechanistic, with active scientific debate.

Here's the puzzle: tirzepatide is a GLP-1 and GIP receptor agonist (it activates both), and it's one of the most effective weight-loss drugs available. MariTide is a GLP-1 agonist and GIP receptor antagonist (it blocks GIP) — and it also drives major weight loss. How can both activating and blocking the same receptor help with obesity? This is a genuine, unresolved question in metabolic pharmacology, not something the marketing has settled.

The leading explanations involve nuances of GIP receptor biology — for instance, that sustained GIP agonism may lead to receptor desensitization that functionally resembles antagonism, or that GIP signalling plays different roles in different tissues (brain versus fat) such that blocking it centrally could still aid weight regulation. The honest takeaway is that the field doesn't fully agree on why GIP antagonism works, only that, empirically, MariTide produces weight loss in trials. That's an important distinction to hold: the clinical results are real and measured, while the mechanistic story is still being written. For the broader landscape of receptor combinations, see our next-gen multi-agonists overview.

How much weight loss does MariTide cause?

Evidence tier: 1 — published Phase 1 and Phase 2 trials.

The early signal came from the Phase 1 trial, where the highest multiple-dose cohort of AMG 133 produced roughly 14.5% mean body-weight reduction by day 85 versus about 1.5% with placebo — a fast, durable effect that justified larger studies (Nature Metabolism Phase 1). The pivotal data then came from the Phase 2 trial, presented at the 2025 American Diabetes Association Scientific Sessions and simultaneously published in the New England Journal of Medicine (Aronne et al. / NEJM 2025; trial NCT05669599).

In that Phase 2 study, MariTide produced up to roughly 20% average weight loss in people with obesity without type 2 diabetes (versus about 2.6% on placebo), and up to roughly 17% in people with obesity and type 2 diabetes, alongside meaningful HbA1c improvements. Critically, the weight-loss curves had not clearly plateaued, suggesting the full effect over a longer treatment course could be larger. Those are strong numbers — competitive with the leading agents — but they come with an important asterisk on tolerability, which is the part Wall Street and clinicians focused on.

What about side effects and tolerability?

Evidence tier: 1 — trial safety data.

MariTide's side-effect profile is the classic incretin pattern — predominantly gastrointestinal: nausea and vomiting — but in the Phase 2 trial these were notable enough to drive relatively high rates of discontinuation, and the vomiting rates in particular drew attention. This is the central open question for the drug: the efficacy is clearly there, but whether people can comfortably stay on it is less settled than for some competitors.

The encouraging part is that the data also showed a fix: starting at lower doses and escalating more gradually substantially improved GI tolerability without sacrificing efficacy. On that basis, Amgen adjusted its Phase 3 dosing strategy to use gentler escalation. So the realistic read is that MariTide's tolerability is a real concern that appears manageable through dosing design — but "appears manageable" is a Phase 2 inference, and Phase 3 will show whether the slower-escalation approach delivers both the weight loss and the staying power. The general principles of managing these GI effects apply across the class, as covered in managing GLP-1 side effects.

There's a structural wrinkle specific to long-acting drugs worth naming. With a weekly injectable, if side effects become intolerable you can hold or reduce the next dose within days. With a monthly drug, once a dose is administered it stays active for weeks, so a bad reaction can't be quickly reversed. That's not a dealbreaker — it's a known feature of long-acting medicines — but it raises the stakes on getting the starting dose and escalation right, and it's part of why the Phase 3 dosing redesign matters so much. The convenience of monthly dosing and the inflexibility of monthly dosing are two sides of the same coin, and how that balance lands in practice is one of the things the larger trials will reveal.

How does MariTide compare to Wegovy, Zepbound, and the pipeline?

Evidence tier: 2 — cross-trial comparison, not head-to-head.

On efficacy, MariTide's ~20% sits in the upper tier alongside tirzepatide (Zepbound) and ahead of semaglutide (Wegovy) in cross-trial terms — but as always, these are not head-to-head trials, and an early-to-mid-phase number shouldn't be ranked directly against a mature Phase 3 result. What genuinely differentiates MariTide isn't a higher number; it's the combination of monthly dosing and a distinct mechanism. Among the pipeline — survodutide (GLP-1/glucagon), amycretin (GLP-1/amylin), retatrutide (triple agonist) — MariTide is the one built around dosing convenience and GIP antagonism (survodutide; amycretin; retatrutide).

Whether that translates into a real-world advantage depends heavily on the tolerability question. A monthly shot is only better than a weekly one if people can tolerate it well enough to stay on it, and a long-acting drug also means side effects can't be dialed back quickly once a dose is given. So MariTide's profile is a genuine trade-off rather than a clear win: convenience and a novel mechanism on one side, tolerability and dosing-flexibility questions on the other. That's the honest framing for a drug still working through Phase 3.

Limitations

This is educational content, not medical advice.

• Efficacy data are Phase 1/Phase 2 — promising and peer-reviewed, but not confirmatory; Phase 3 is ongoing.
• Tolerability is the key open question — Phase 2 saw high GI and discontinuation rates, now being addressed via dosing.
• The GIP-antagonism mechanism isn't fully understood — the clinical effect is measured; the explanation is debated.
• Cross-trial comparisons aren't head-to-head — don't directly rank MariTide vs tirzepatide/semaglutide numbers.
• Not approved anywhere — online "MariTide/maridebart" is gray-market and not genuine.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

MariTide (maridebart cafraglutide) is one of the more distinctive obesity drugs in development: a once-monthly peptide-antibody conjugate that combines GLP-1 agonism with GIP receptor antagonism, delivering up to ~20% weight loss in a Phase 2 trial. Its appeal is convenience and a novel mechanism; its open question is tolerability, with Phase 2 showing high GI and discontinuation rates that Amgen is addressing through gentler Phase 3 dosing. It's investigational and not approved, so anything sold as "MariTide" online is fake. For anyone tracking where obesity treatment is heading, it's a genuinely interesting entrant to watch — but its real-world place depends on Phase 3 answering whether people can comfortably stay on it.

Related on this site

• GLP-1 complete guide
• Next-gen multi-agonists overview
• Survodutide (glucagon/GLP-1) explained
• Amycretin (GLP-1/amylin) explained
• Managing GLP-1 side effects
• Our evidence-tier framework

References

• Aronne LJ, et al. 2025. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. N Engl J Med. doi:10.1056/NEJMoa2504214 — Phase 2 efficacy and tolerability.
• Véniant MM, et al. 2024. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab 6:290–303. doi:10.1038/s42255-023-00966-w — Phase 1 results and mechanism.
• Phase 2 obesity trial of maridebart cafraglutide. ClinicalTrials.gov NCT05669599 — trial registration and design.